<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02781259</url>
  </required_header>
  <id_info>
    <org_study_id>2015-01-046-007</org_study_id>
    <nct_id>NCT02781259</nct_id>
  </id_info>
  <brief_title>Selective Lymph Node Dissection Using Fluorescent Dye in Node-positive Breast Cancer</brief_title>
  <official_title>Selective Lymph Node Dissection Using Fluorescent Dye in Node-positive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, navigation of lymphatic passage after sentinel lymph node with indocyanine
      green was performed during axillary lymph node dissection in breast surgery . By comparing
      the concordance between the passage of indocyanine green and actual lymph node metastasis,
      selective lymph node dissection can be developed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Low dose of indocyanine green emits near-infrared fluorescence, which can penetrate thin
      tissues like breast or skin. The operator can track the lymphatic pathway without skin
      incision in real time. By these characteristics, indocyanine green is currently used for
      sentinel lymph node biopsy in breast cancer surgery. Indocyanine green can also stain lymph
      nodes beyond the sentinel lymph nodes. This is why we can identify the lymphatic metastasis
      pathway of breast cancer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of metastatic lymph nodes in fluorescent positive lymph nodes and fluorescent negative lymph nodes confirmed by pathologist</measure>
    <time_frame>within 2 weeks (plus or minus 3 days) after surgery</time_frame>
    <description>Concordance analysis is done by comparing lymph node metastasis between fluorescent positive lymph nodes and fluorescent negative lymph nodes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinicopathological factors associated with lymph node metastasis in fluorescent negative lymph nodes</measure>
    <time_frame>within 2 weeks (plus or minus 3 days) after surgery</time_frame>
    <description>Risk factor analysis of fluorescent negative lymph node with positive lymph node metastasis</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Selective Lymph Node Dissection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10cc of 20μg/mL indocyanine green is injected at the nipple-areola complex before surgery. Routine axillary lymph node dissection is performed. Acquired lymph nodes are separated to fluorescent positive lymph nodes and fluorescent negative lymph nodes with imaging devices.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Axillary lymph node dissection</intervention_name>
    <description>Lymph node dissection is performed in axillary lymph node level I and II. In case of palpable nodes in level II, additional lymph node dissection in level III is done.</description>
    <arm_group_label>Selective Lymph Node Dissection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indocyanine green</intervention_name>
    <description>10cc of 20μg/mL indocyanine green is injected at the nipple-areola complex before surgery</description>
    <arm_group_label>Selective Lymph Node Dissection</arm_group_label>
    <other_name>Diagnogreen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Imaging devices</intervention_name>
    <description>Near-infrared fluorescence is collected by imaging lenses and digital camera.</description>
    <arm_group_label>Selective Lymph Node Dissection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Operable breast cancer patient

          -  Preoperatively axillary lymph node positive proven patients or sentinel lymph node
             positive patients whom requires axillary lymph node dissection

        Exclusion Criteria:

          -  Breast cancer history

          -  Occult breast cancer

          -  Past history of axillary surgery

          -  Iodine hypersensitivity

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>SeokWon Kim, MD. PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>SeokWon Kim, MD. PhD.</last_name>
    <phone>+82-2-3410-3479</phone>
    <email>seokwon1.kim@samsung.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Samsung medical center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SeokWon Kim, Md. PhD</last_name>
      <phone>+82-2-3410-3479</phone>
      <email>seokwon1.kim@samsung.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2016</study_first_submitted>
  <study_first_submitted_qc>May 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2016</study_first_posted>
  <last_update_submitted>September 18, 2016</last_update_submitted>
  <last_update_submitted_qc>September 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Seok Won Kim</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>Sentinel Lymph Node Biopsy</keyword>
  <keyword>Fluorescence</keyword>
  <keyword>Breast Neoplasms</keyword>
  <keyword>Indocyanine Green</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

